Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 5Phase 3 4Phase 4 2Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Vomiting 1Nausea 1Multiple Myeloma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × fosaprepitant × Clear all
NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
22 enrolled 16 charts
Plasma cell

Multiple Myeloma

NCT01031953 2017-05-09

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

OHSU Knight Cancer Institute

Phase 1/2 Terminated
34 enrolled 12 charts

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡